Related Experiment Video
Updated: Jan 10, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Breast Cancer in Kazakhstan, 2004-2023: Successful Mortality Reduction Driven by Organized Screening and Stage Shift
Nurbek Igissin1,2,3, Zhansaya Telmanova2,4, Indira Kudaibergenova2,3,4
1Research Institute of Life and Health Sciences, Higher School of Medicine, Kokshetau University named after Sh. Ualikhanov, Kokshetau, Kazakhstan.
Objective:
To quantify two-decade national trends in the breast cancer burden in Kazakhstan and evaluate the performance of the organized mammography screening programme-including stage distribution and regional heterogeneity after its scale-up.
Methods:
We conducted a retrospective, population-based evaluation using national registry and screening data. Population indicators (incidence, mortality, years of potential life lost) were analysed for 2004-2023; screening performance (coverage, abnormal rate, cancer detection rate, positive predictive value, benign biopsy rate, number needed to screen, programme contribution) was assessed for 2010-2023. Trends were modelled with Joinpoint; staging followed TNM (I-II "early", III-IV "advanced").
Results:
ASIR increased from 39.3 per 100,000 women in 2004 to 54.4 in 2023 (with a transient dip to 44.9 in 2020), whereas ASMR declined from 16.6 to 10.2 per 100,000 over the same interval; the mortality-to-incidence ratio decreased from 0.42 to 0.19. YPLL_75 fell from 175.1 per 100,000 in 2004 to a nadir of 76.0 in 2018, then measured 104.9 in 2023. The proportion diagnosed at stages I-II rose from 71.1% (2010) to 88.6% (2023), with corresponding declines in stage III (22.2% → 8.7%) and stage IV (6.8% → 5.1%). Following the expansion of eligibility to ages 40-70 (from 2018), screening throughput and coverage increased, but performance remained heterogeneous across regions, with variability in recall rates, detection yield, and downstream diagnostic pathways.
Conclusion:
Across 2004-2023, Kazakhstan experienced a favourable divergence between rising incidence and falling mortality, substantial reductions in premature mortality, and a marked shift toward earlier-stage diagnosis. These gains coincide with the maturation of the organised screening programme and broader system improvements. Consolidation will require targeted, region-specific quality-improvement bundles and resilience strategies to protect screening coverage and diagnostic capacity during system shocks.
More Related Videos
03:07Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial
Published on: August 19, 2025
12:24A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Related Concept Videos
Cancer Survival Analysis
Cancer Prevention
Some...
Primary Healthcare Services
In 1978, international leaders convened in Alma-Ata, Kazakhstan, for what would be a pivotal event in global health. The Alma-Ata Declaration was the first to call...
Preventive Healthcare Services